Global E-Cigarette Liquid Market to Reach $37 Billion by 2028

Aug.23.2022
Global E-Cigarette Liquid Market to Reach $37 Billion by 2028
The global e-cigarette liquid market is projected to reach $3.7 billion by 2028, driven by increasing health awareness and demand for safer smoking alternatives.

Market.US has released a research report stating that the global e-cigarette e-liquid market was valued at $1.7 billion in 2020 and is expected to reach $3.7 billion by 2028. The market is projected to grow at a CAGR of 12.8% from 2021 to 2028.


An increasing number of people are turning to safer smoking alternatives as awareness regarding health issues continues to grow. Electronic cigarettes are known to contain lower levels of toxic substances, and offer various flavors such as tobacco, mint, fruit, and nut. This is expected to fuel the consumption of e-cigarette oil.


Electronic cigarettes, unlike traditional tobacco cigarettes, do not contain tobacco and do not produce tar or carbon monoxide. This makes them a safer alternative to smoking. As people become more aware of the harmful effects of smoking on their health, they are more likely to quit, leading to a positive impact on the global sales of electronic cigarettes. This is one of the many reasons why the electronic cigarette industry is thriving.


Global E-liquid Market: Driving Factors


Electronic cigarette liquid is often used as a substitute for traditional tobacco. E-cigarette liquid can be infused with many flavors, providing a fresh and enhanced taste.


Electronic cigarettes are different from traditional cigarettes in that they allow you to inhale fewer toxic substances, reducing the risk of lung disease. These factors are expected to drive growth in the global liquid market. The use of e-liquid in electronic cigarettes helps reduce environmental damage, which is why manufacturers are focusing on liquid e-cigarettes, which are becoming increasingly popular. Green e-cigarettes are an obvious trend, eliminating the environmental burden associated with handling large amounts of cigarette butts.


Furthermore, electronic cigarettes reduce the issue of deforestation and the environmental degradation caused by tobacco production. Compared to traditional smoking, electronic cigarettes provide many advantages to smokers, helping them to reduce their intake of tar and nicotine and leading many to partially or completely quit smoking. These health benefits are driving demand for liquid nicotine in the electronic cigarette market. However, government regulation of e-cigarettes as tobacco products may hinder the future growth of the global e-liquid market.


The main trend in the market: Nicotine salts.


E-cigarettes are considered safer because they do not burn tobacco or produce tar or carbon monoxide. As knowledge about e-cigarettes increases, sales have also been on the rise. This is one of the main factors driving the growth of the e-cigarette oil market. Health authorities and organizations around the world are taking measures to reduce tobacco use, including indoor smoking bans and high taxes. This has encouraged people to use e-cigarettes as a means to quit smoking and has driven market growth.


Leading manufacturers are utilizing social media to promote their products, providing customized flavors, and implementing innovative marketing strategies. Online distribution channels are also being used for e-cigarette accessories and kits. With both open and closed systems becoming increasingly popular, there is an expected increase in global demand. The research report addresses the following questions:


Who are the main players in the electronic e-liquid market? What are the main driving factors for the growth of the electronic e-liquid market? Based on what types of categories is the global electronic e-liquid market classified? What is the expected market size and growth rate of the electronic e-liquid market in the future? In 2021, which distribution channels dominate the electronic e-liquid industry? What criteria are used when selecting companies?


Click to view a sample research report.


Statement


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The compilation of this article is only intended for industry communication and research.


Due to the limitations of the translation ability, the translated article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong-Macau-Taiwan-related, and foreign related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
According to WNCY on August 24, 2026, some independent vape retailers in Wisconsin say they have faced significant business pressure one year after new vape regulations took effect. Johnny Vapes, a retailer operating in northeast Wisconsin, said its store count fell from seven locations to four, sales declined by about 80%, and roughly 90% of its inventory was affected. Retailers said some consumers have shifted to online purchases or traveled to neighboring Michigan to buy vape products. The case highlights how local regulations can reshape retail operations, inventory management and consumer purchasing patterns.
Aug.28
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07